Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. This is a 28-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to insulin in people with type 2 diabetes who are not at target blood glucose levels on insulin alone. The purpose of the extension study is to gather data on the long-term safety and effectiveness of vildagliptin in people with type 2 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
179
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
Novartis Investigative Site
Investigative Centers, Germany
Safety of vildagliptin in combination with insulin during 52 weeks of treatment
Change from baseline in HbA1c at 52 weeks
Change in HbA1c between 24 weeks and 52 weeks
Change in fasting plasma glucose between 24 weeks and 52 weeks
Change from baseline in fasting plasma glucose at 52 weeks
Change from baseline in mean daily insulin dose at 52 weeks
Change from baseline in mean daily number of insulin injections at 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.